Board Change • 10h
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Hanming Yang was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Aankondiging • Apr 14
Hangzhou DPtech Technologies Co.,Ltd., Annual General Meeting, May 07, 2026 Hangzhou DPtech Technologies Co.,Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: 3F, No. 595, Yueming Road, Binjiang District, Hangzhou, Zhejiang China Aankondiging • Mar 31
Hangzhou DPtech Technologies Co.,Ltd. to Report Q1, 2026 Results on Apr 14, 2026 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report Q1, 2026 results on Apr 14, 2026 Aankondiging • Dec 31
Hangzhou DPtech Technologies Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 14, 2026 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 14, 2026 Aankondiging • Sep 30
Hangzhou DPtech Technologies Co.,Ltd. to Report Q3, 2025 Results on Oct 24, 2025 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025 Aankondiging • Jul 02
Hangzhou DPtech Technologies Co.,Ltd. to Report First Half, 2025 Results on Aug 05, 2025 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report first half, 2025 results on Aug 05, 2025 Aankondiging • Apr 16
Hangzhou Dptech Technologies Co.,Ltd. Proposes Cash Dividend for the Year 2024 Hangzhou DPtech Technologies Co.,Ltd. announced on 15 April 2025 the profit distribution proposal for 2024 as Cash dividend/10 shares (tax included): CNY 0.80000000. Aankondiging • Apr 15
Hangzhou DPtech Technologies Co.,Ltd., Annual General Meeting, May 07, 2025 Hangzhou DPtech Technologies Co.,Ltd., Annual General Meeting, May 07, 2025, at 14:00 China Standard Time. Location: 3F, No. 595, Yueming Road, Binjiang District, Hangzhou, Zhejiang China Aankondiging • Mar 31
Hangzhou DPtech Technologies Co.,Ltd. to Report Q1, 2025 Results on Apr 15, 2025 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report Q1, 2025 results on Apr 15, 2025 Aankondiging • Dec 31
Hangzhou DPtech Technologies Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025 Reported Earnings • Oct 23
Third quarter 2024 earnings released: EPS: CN¥0.074 (vs CN¥0.054 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.074 (up from CN¥0.054 in 3Q 2023). Revenue: CN¥316.8m (up 14% from 3Q 2023). Net income: CN¥40.3m (up 46% from 3Q 2023). Profit margin: 13% (up from 10.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥16.11, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 33x in the Software industry in China. Total loss to shareholders of 45% over the past three years. Aankondiging • Sep 30
Hangzhou DPtech Technologies Co.,Ltd. to Report Q3, 2024 Results on Oct 23, 2024 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report Q3, 2024 results on Oct 23, 2024 Reported Earnings • Aug 06
Second quarter 2024 earnings released: EPS: CN¥0.022 (vs CN¥0.01 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.022 (up from CN¥0.01 in 2Q 2023). Revenue: CN¥247.8m (up 17% from 2Q 2023). Net income: CN¥15.4m (up 127% from 2Q 2023). Profit margin: 6.2% (up from 3.2% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Aankondiging • Jul 08
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class LP-PLA2 Inhibitor for DR and DME DP Technology announced the nomination of DPT0415, a novel small molecule targeting Lipoprotein-associated phospholipase A2 (Lp-PLA2), as a preclinical candidate compound for the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME). Lp-PLA2 belongs to group VII of the PLA2 superfamily, primarily secreted by macrophages and circulates in the blood as a complex with low-density lipoprotein (LDL) and high-density lipoprotein (HDL). Lp-PLA2 hydrolyzes oxidized phospholipids, typically on low-density lipoprotein (LDL) to generate lysophosphatidylcholine (lysoPC). LysoPC induces vascular inflammation, leading to damage to the blood-retinal barrier (BRB). DR is a microvascular complication of diabetes and a major cause of vision loss in middle-aged and elderly people. One-third of people with diabetes have DR. DME can occur at any stage of DR, which is caused by excess fluid and lipid accumulation in the macula due to a breakdown in the blood-retinal barrier. When the edema extends into the fovea, the patient becomes symptomatic with metamorphopsia and vision loss. The advent of intraocular anti-vascular endothelial growth factor (anti-VEGF) drugs has revolutionized the treatment of DME. However, many patients with DME do not show complete resolution of fluid despite multiple injections, probably because DR is also an inflammatory disease with many cytokines and chemokines involved in the process[6]. Thus, the molecular mechanisms beyond VEGF should be explored. As a Lp-PLA2 inhibitor, oral administration of Darapladib modestly reduced edema and improved vision in a center-involved DME phase IIa study. DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with a novel scaffold. It demonstrated sufficient target engagement at 0.3 mpk, and resecured retinopathy in the STZ-induced rat DR model. The compound exhibits higher potency, better ADME and physicochemical properties than Darapladib, and demonstrated sufficient safety margin in preclinical studies. The RiDYMO drug design platform integrates various AI and physical algorithms, dedicated to the development of drugs for "undruggable" targets and "best-in-class" molecules. As one of its core algorithms, Reinforced Dynamics (RiD) has a significant advantage in the sampling efficiency of molecular dynamics simulation. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD can efficiently capture dynamic conformational changes in complicated biomolecular systems. The RiDYMO® platform is dedicated to studying the dynamics of biological systems and revealing cryptic binding sites, encompassing a range of challenging systems including protein-protein interactions (PPIs), intrinsically disordered proteins (IDPs), membrane proteins, RNA, and others. Its effectiveness has been confirmed through validation on challenging targets, including the c-Myc protein, c-Myc RNA, GPX4 protein, Kv1.3 protein, and others. Buy Or Sell Opportunity • Jul 01
Now 12% overvalued Over the last 90 days, the stock has fallen 4.3% to CN¥11.65. The fair value is estimated to be CN¥10.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 37%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 98% in the next 2 years. Aankondiging • Jun 29
Hangzhou DPtech Technologies Co.,Ltd. to Report First Half, 2024 Results on Aug 06, 2024 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report first half, 2024 results on Aug 06, 2024 Buy Or Sell Opportunity • Jun 26
Now 27% overvalued The stock has been flat over the last 90 days, currently trading at CN¥12.01. The fair value is estimated to be CN¥9.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 37%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 98% in the next 2 years. Declared Dividend • May 17
Dividend of CN¥0.08 announced Dividend of CN¥0.08 is the same as last year. Ex-date: 22nd May 2024 Payment date: 22nd May 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (38% earnings payout ratio) and cash flows (75% cash payout ratio). The dividend has decreased by an average of 1.0% per year over the past 4 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 111% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • May 16
Hangzhou DPtech Technologies Co.,Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 22 May 2024 Hangzhou DPtech Technologies Co.,Ltd. announced 2023 final profit distribution plan to be implemented (A shares) cash dividend of CNY 0.80000000 /10 shares (tax included). Payment date: 22 May 2024. Record date: 21 May 2024. Ex-date: 22 May 2024. Aankondiging • May 11
Hangzhou Dptech Technologies Co.,Ltd. Approves Cash Dividend for the Year 2023 Hangzhou DPtech Technologies Co.,Ltd. held its Annual General Meeting of 2023 on 08 May 2024 were approved 2023 profit distribution plan as Cash dividend/10 shares (tax included): CNY 0.80000000. Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥13.99, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 30x in the Software industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥9.42 per share. Reported Earnings • Apr 18
First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.05 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.06 (up from CN¥0.05 in 1Q 2023). Revenue: CN¥254.7m (up 10% from 1Q 2023). Net income: CN¥36.7m (up 12% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings. Aankondiging • Apr 16
Hangzhou DPtech Technologies Co.,Ltd., Annual General Meeting, May 08, 2024 Hangzhou DPtech Technologies Co.,Ltd., Annual General Meeting, May 08, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hangzhou, Zhejiang China Aankondiging • Mar 30
Hangzhou DPtech Technologies Co.,Ltd. to Report Q1, 2024 Results on Apr 16, 2024 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report Q1, 2024 results on Apr 16, 2024 Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥9.99, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 28x in the Software industry in China. Total loss to shareholders of 59% over the past three years. Aankondiging • Jan 23
Hangzhou DPtech Technologies Co.,Ltd. (SZSE:300768) announces an Equity Buyback for CNY 100 million worth of its shares. Hangzhou DPtech Technologies Co.,Ltd. (SZSE:300768) announces a share repurchase program. Under the program, the company will repurchase not more than CNY 100 million worth of its shares. The shares will be repurchased at a price not more than CNY 20 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The program will be valid for a period of 12 months. Aankondiging • Dec 29
Hangzhou DPtech Technologies Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.054 (vs CN¥0.042 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.054 (up from CN¥0.042 in 3Q 2022). Revenue: CN¥277.9m (up 17% from 3Q 2022). Net income: CN¥27.7m (up 2.0% from 3Q 2022). Profit margin: 10.0% (down from 11% in 3Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Aankondiging • Sep 30
Hangzhou DPtech Technologies Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 17
Second quarter 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.007 loss in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.01 (up from CN¥0.007 loss in 2Q 2022). Revenue: CN¥211.0m (up 37% from 2Q 2022). Net income: CN¥6.76m (up CN¥11.1m from 2Q 2022). Profit margin: 3.2% (up from net loss in 2Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 19% per year. Aankondiging • Jul 01
Hangzhou DPtech Technologies Co.,Ltd. to Report First Half, 2023 Results on Aug 17, 2023 Hangzhou DPtech Technologies Co.,Ltd. announced that they will report first half, 2023 results on Aug 17, 2023 Aankondiging • May 25
Hangzhou DPtech Technologies Co.,Ltd. Implements Final Cash Dividend of A Shares for the Year 2022, Payable on May 30, 2023 Hangzhou DPtech Technologies Co.,Ltd. implemented final Cash dividend of CNY 0.80000000 per 10 A shares (tax included) for the year 2022. Record date: 29 May 2023; Ex-date: 30 May 2023; Payment date: 30 May 2023. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.05 (vs CN¥0.071 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.05 (down from CN¥0.071 in 1Q 2022). Revenue: CN¥231.2m (up 8.1% from 1Q 2022). Net income: CN¥32.6m (down 28% from 1Q 2022). Profit margin: 14% (down from 21% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has fallen by 15% per year whereas the company’s share price has fallen by 17% per year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Nov 02
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥16.69, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 31x in the Software industry in China. Total loss to shareholders of 28% over the past three years. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.042 (vs CN¥0.17 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.042 (down from CN¥0.17 in 3Q 2021). Revenue: CN¥238.4m (down 23% from 3Q 2021). Net income: CN¥27.1m (down 73% from 3Q 2021). Profit margin: 11% (down from 32% in 3Q 2021). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Software industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥13.26, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 28x in the Software industry in China. Total loss to shareholders of 49% over the past three years. Reported Earnings • Jul 30
Second quarter 2022 earnings released: CN¥0.007 loss per share (vs CN¥0.096 profit in 2Q 2021) Second quarter 2022 results: CN¥0.007 loss per share (down from CN¥0.096 profit in 2Q 2021). Revenue: CN¥154.3m (down 36% from 2Q 2021). Net loss: CN¥4.37m (down 107% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 43%, compared to a 31% growth forecast for the industry in China. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Non-Independent Director Qiang Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Buying Opportunity • Apr 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 36%. The fair value is estimated to be CN¥30.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 71% in 2 years. Earnings is forecast to grow by 81% in the next 2 years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.17 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥309.1m (up 30% from 3Q 2020). Net income: CN¥99.2m (up 43% from 3Q 2020). Profit margin: 32% (up from 29% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.11 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥239.2m (up 34% from 2Q 2020). Net income: CN¥58.9m (up 28% from 2Q 2020). Profit margin: 25% (down from 26% in 2Q 2020). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥44.82, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 35x in the Software industry in China. Total loss to shareholders of 17% over the past year. Reported Earnings • Apr 25
First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.099 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2021 results: Revenue: CN¥193.8m (up 40% from 1Q 2020). Net income: CN¥46.5m (up 17% from 1Q 2020). Profit margin: 24% (down from 29% in 1Q 2020). The decrease in margin was driven by higher expenses. Is New 90 Day High Low • Mar 03
New 90-day high: CN¥41.56 The company is up 5.0% from its price of CN¥39.71 on 03 December 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 17
New 90-day low: CN¥36.24 The company is down 14% from its price of CN¥42.13 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is down 5.0% over the same period. Is New 90 Day High Low • Nov 27
New 90-day low: CN¥39.28 The company is down 12% from its price of CN¥44.45 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is down 11% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥250.0m, up 11% from the prior year. Total revenue was CN¥815.3m over the last 12 months, up 6.3% from the prior year.